. Author manuscript; available in PMC: 2016 Aug 4.

Published in final edited form as: Pract Radiat Oncol. 2015 Nov 11;6(2):e27–e33. doi: 10.1016/j.prro.2015.09.012

Table 2.

Characteristics of patients experiencing SBRT-related death

	Patient 1	Patient 2	Patient 3	Patient 4
Clinical scenario	75-year-old woman T1bN0 NSCLC	67-year-old man T2aN0 NSCLC	54-year-old man Oligometastatic NSCLC	49 year-old man Oligometastatic colorectal cancer
Tumor location	LLL	LLL	LLL	LLL
Tumor size	2.4 × 2.1 cm	4.1 × 3.6 cm	2.9 × 1.7 cm	2.4 × 2.3 cm
History of anti-VEGF therapy	No	No	Yes	Yes
Prescription dose	4500 cGy (9 Gy × 5)	4500 cGy (9 Gy × 5)	4500 cGy (9 Gy × 5)	5000 cGy (10 Gy × 5)
Cause of death	Sepsis from pneumonia, 8 months after SBRT	Acute respiratory failure and pneumonia, 7 months after SBRT	Acute pulmonary hemorrhage, 10 months after SBRT	Acute pulmonary hemorrhage, 9 months after SBRT
GTV/PTV size (mL)	24.2/93.3	74.4/181	16.0/99.6	20.2/94.7
Max point dose to PBT/NFZ (cGy)	4488/4776	4501/4526	4720/4940	5144/5406
Ipsilateral/bilateral lung V20 (%)	19.4/8.8	22.0/8.2	18.4/7.4	24.5/11.0

GTV, gross tumor volume; L, left; LLL, left lower lobe; NFZ, no-fly zone; NSCLC, non-small cell lung cancer; PBT, proximal bronchial tree; PTV, planning target volume; SBRT, stereotactic body radiation therapy; V20, percentage of normal tissue receiving 20 Gy or greater; VEGF, vascular endothelial growth factor.